Povorcitinib (INCB054707) is a potent, selective and oral JAK1 inhibitor with IC50 of 8.9 nM, 52-fold selective over JAK2 (IC50=463 nM).
Povorcitinib (INCB054707) reduces IFN signaling and ameliorates cutaneous lesions in systemic lupus erythematosus (SLE).
Povorcitinib (INCB054707) dose-dependently reduced the incidence and severity of cutaneous lesion, abrogated lymphoid tissue and spleen enlargement in a preclinical model of cutaneous lupus erythematosus.
